- IN8bio's INB-200 therapy for glioblastoma multiforme shows a median progression-free survival (mPFS) of 16.1 months, significantly exceeding the typical 6.9 months observed with the standard Stupp protocol.
- The treatment remains safe, displaying no serious toxicities, cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS).
- Promising results for INB-400 with early Phase 2 data reveal a median progression-free survival of 10.8 months.
IN8bio, Inc. (INAB, Financial), a clinical-stage biopharmaceutical company, has announced positive Phase 1 trial results for INB-200, an innovative gamma-delta T cell therapy for newly diagnosed glioblastoma multiforme (GBM). The results reveal a median progression-free survival (mPFS) of 16.1 months for patients receiving multiple doses, an astonishing improvement over the 6.9 months typically seen with the standard-of-care Stupp protocol.
Importantly, INB-200 has shown a favorable safety profile. Throughout the trial, no serious toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity syndrome were observed. This safety record holds significant implications for the potential success of the treatment in broader clinical applications.
Additionally, in a promising advancement, preliminary Phase 2 trial data for INB-400, another therapy being developed by IN8bio, indicate a median progression-free survival of 10.8 months. Further updates on the Phase 2 results are expected later in 2025.
These developments underscore IN8bio's potential to revolutionize treatments for GBM, particularly for the challenging chemotherapy-resistant cases. The company’s approach, which combines INB-200 with standard maintenance chemotherapy, offers hope for improved patient outcomes, including extended survival and enhanced quality of life.
